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Background: PRDM5 is an epigenetic regulator that has been recognized as an important tumour suppressor gene.
Silencing of PRDM5 by promoter hypermethylation has been demonstrated in several cancer types and PRDM5 loss
results in upregulation of the Wnt pathway and increased cellular proliferation. PRDM5 has not been extensively
investigated in specific subtypes of colorectal cancers. We hypothesized it would be more commonly methylated
and inactivated in serrated pathway colorectal cancers that are hallmarked by a BRAF V600E mutation and a
methylator phenotype, compared to traditional pathway cancers that are BRAF wild type.
Methods: Cancer (214 BRAF mutant, 122 BRAF wild type) and polyp (59 serrated polyps, 40 conventional
adenomas) cohorts were analysed for PRDM5 promoter methylation using MethyLight technology. PRDM5 protein
expression was assessed by immunohistochemistry in cancers and polyps. Mutation of PRDM5 was analysed using
cBioPortal’s publicly available database.
Results: BRAF mutant cancers had significantly more frequent PRDM5 promoter methylation than BRAF wild type
cancers (77/214,36% vs 4/122,3%; p<0.0001). Serrated type polyps had a lower methylation rate than cancers but
were more commonly methylated than conventional adenomas (6/59,10% vs 0/40,0%). PRDM5 methylation was
associated with advanced stages of presentation (p<0.05) and the methylator phenotype (p=0.03). PRDM5 protein
expression was substantially down-regulated in both BRAF mutant and wild type cancer cohorts (92/97,95% and
39/44,89%). The polyp subgroups showed less silencing than the cancers, but similar rates were found between the
serrated and conventional polyp cohorts (29/59, 49%; 23/40, 58% respectively). Of 295 colorectal cancers, PRDM5
was mutated in only 6 (2%) cancers which were all BRAF wild type.
Conclusions: Serrated pathway colorectal cancers demonstrated early and progressive PRDM5 methylation with
advancing disease. Interestingly, PRDM5 protein expression was substantially reduced in all polyp types and more so in
cancers which also indicates early and increasing PRDM5 down-regulation with disease progression. Methylation may be
contributing to gene silencing in a proportion of BRAF mutant cancers, but the large extent of absent protein expression
indicates other mechanisms are also responsible for this. These data suggest that PRDM5 is a relevant tumour suppressor
gene that is frequently targeted in colorectal tumourigenesis.
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PR (PRDI-BF1 and RIZ) domain (PRDM) proteins are a
family of zinc finger transcription factors whose PR
domain shares homology to the SET domain that is often
present in proteins with chromatin modifying activity [1].
PRDM5 is an epigenetic regulator that does not possess this
specific activity itself, however its 16 zinc fingers facilitates
sequence specific protein and DNA interactions with a
multitude of genes including histone methyltransferases
and deacetylases [2-4]. PRDM5 recruits and directs these,
specifically G9A and HDAC1, towards the promoters of its
target genes to cause repression via chromatin modification
[3]. PRDM5 has also been found to activate genes by
maintaining RNA polymerase II at its target’s promoters
[5]. Loss of PRDM5 is associated with bone morphogenic
and developmental defects [5,6], and infrequent mutations
of PRDM5 have been found in brittle cornea syndrome
and neutropenia [3,7].
Studies have shown its promoter region contains a
CpG island that is epigenetically silenced by methylation
in several different cancer cell lines and primary cancers
including breast, liver, gastric, lung, nasopharyngeal and
esophageal [2,4,8,9]. Functional studies have identified
PRDM5 as a tumour suppressor gene due to its role in
suppressing cell growth and proliferation [4,8], in regulation
of the cell cycle at the G2/M checkpoint [2,3] and as a heat
shock responsive gene [8]. Furthermore, PRDM5 has been
associated with inhibition of the Wnt pathway [6], where
its overexpression prevented TCF/beta-catenin dependent
transcription and repressed the downstream Wnt target,
CDK4 in cancer cell lines [8]. Additionally, PRDM5 loss
resulted in increased adenoma burden in mice models that
had a deregulated Wnt pathway background [10].
Despite several cancers identified as having frequent
PRDM5 promoter methylation, only minimal rates of
methylated PRDM5 has been found in an uncharacterized
series of colorectal cancers [4]. In a specific subgroup of
colorectal cancers, there is frequent widespread methylation
of promoter regions and subsequent silencing of key
tumour suppressor genes, which is termed the CpG Island
Methylator Phenotype (CIMP) [11,12]. These cancers derive
from serrated type precursor lesions and are hallmarked by
aV600E BRAF mutation, which with the onset of CIMP are
early events in this ‘serrated pathway’ of tumourigenesis
[13]. Cancers that follow the serrated pathway account for
approximately 15% of all colorectal cancers. Approximately
half of these cancers methylate a DNA mismatch repair
gene, MLH1, and develop microsatellite instability
(MSI) [14,15], and the remaining half stay as microsatellite
stable (MSS).
The most common form of colorectal cancer originates
from a conventional adenoma. These follow a ‘traditional
pathway’ in which key molecular events, such as mutations
of APC and KRAS, have been previously well defined[16] and result in cancers that are BRAF wild type
and microsatellite stable.
This study has investigated whether PRDM5 methylation
is a target of epigenetic silencing more commonly in the
serrated compared to the traditional pathway of colorectal
cancer. This was examined in both cancer and precursor
lesion subgroups to give an indication of when
PRDM5 is downregulated in tumourigenesis. PRDM5
protein expression was also examined in cancer and
polyp subgroups, and PRDM5 mutation frequency was
investigated using a publicly available database.
Methods
Patient samples
A total of 214 BRAF mutant (120 BRAF mutant/MSI
and 94 BRAF mutant/MSS) and 122 BRAF wild type
cancers were obtained either as fresh frozen tissue after
surgical excision from the Royal Brisbane and Women’s
Hospital (RBWH), Brisbane, Australia as previously
described [17,18], or as formalin-fixed paraffin embedded
(FFPE) tissue from Envoi Specialist Pathologists, Brisbane,
Australia. Written, informed consent was obtained from
each patient involved in this research which was approved
by the Royal Brisbane and Women’s Hospital and Bancroft
Human Research Ethics Committee. Clinicopathological
data of patient gender, age at diagnosis, anatomical site of
cancer (with proximal termed if proximal to the splenic
flexure), and cancer stage (according to the American
Joint Committee on Cancer, AJCC, system) were collected
where available.
Polyp cohorts consisting of 59 serrated type polyps
(19 microvesicular hyperplastic polyps, MVHPs; 20
sessile serrated adenomas, SSAs; and 20 traditional
serrated adenomas, TSAs) and 40 conventional polyps
(20 of each tubular adenomas, TAs; and tubulovillous
adenomas, TVAs) were collected as FFPE tissue from
Envoi Specialist Pathologists.
DNA from fresh cancer and matched normal tissue was
extracted using AllPrep DNA mini kit (Qiagen, Dusseldorf,
Germany). DNA from the FFPE cancer and polyp and
matched normals were extracted by the Chelex-100
method (Bio-Rad Laboratories, CA, USA).
The presence of MSI had been previously analysed for
the RBWH’s cancer samples using the National Cancer
Institute’s 5 marker panel [17,19]. Cancers from Envoi
Pathologists were evaluated for immunohistochemical
loss of mismatch repair protein expression (MLH1,
PMS2, MSH6, MSH2) as a surrogate for MSI. Presence
of the BRAF V600E (a1796t) mutation, p53 mutation
(over exons 4–8) and KRAS mutation (over codons 2 and 3)
had been previously investigated for the RBWH’s samples
[17]; presence of BRAF V600E (a1796t) and KRAS (codons
2 and 3) mutations was analysed for Envoi’s samples
as previously described [17,20-22].
Table 1 Clinical and molecular features of cancer cohorts
BRAF mutant BRAF wild
type
P value
N 214 122 -
Average Age (years) 74.1 67.1 <0.0001
Gender - female 139/214 (65.0%) 49/122 (40.2%) <0.0001
Tumour Location (Proximal) 164/192 (85.4%) 28/117 (23.9%) <0.0001
AJCC stage I/II 110/170 (64.7%) 58/111 (52.3%) <0.05
AJCC stage III/IV 60/170 (35.3%) 53/111 (47.7%)
Mucinous 37/96 (38.5%) 3/42 (7.1%) <0.0001
Differentiation (poor) 38/96 (39.6%) 12/42 (28.6%) 0.2
MSI High 120/214 (56.1%) 0 -
CIMP High 154/205 (75.1%) 3/121 (2.5%) <0.0001
p53 Mutation 29/107 (27.1%) 40/80 (50.0%) 0.002
KRAS Mutation 0 38/80 (47.5%) -
PRDM5 Methylation 77/214 (36.0%) 4/122 (3.3%) <0.0001
PRDM5 PMR 27 3 <0.0001
Nuclear Beta-Catenin 36/92 (39.1%) 36/42 (85.7%) <0.0001
Significant p values indicated in bold text.
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PRDM5 Methylation-Specific PCR
Sample DNA was bisulfite modified using Epitect Fast
Bisulfite Conversion kit (Qiagen, Dusseldorf, Germany).
CIMP was assessed in cancer and polyp cohorts using
MethyLight technology over a 5 marker panel consisting
of CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 as
previously described by Weisenberger et al. [17,22-24].
Percent of methylated reference (PMR) indicates the
extent of methylation of a sample in relation to a
methylated reference, and a sample with a PMR of
≥10 was considered as methylated at that marker
[22]. If ≥3 markers were methylated the sample was
considered CIMP-high, with 1–3 markers methylated
the sample was termed CIMP-low and CIMP-0 if no
markers were methylated [22]. For MSP of PRDM5,
the same PMR cutoff of ≥10 applied for a sample to
be considered methylated, a sample with a PMR <10 was
considered unmethylated. For all CIMP markers and the
PRDM5 MSPs, an Alu assay was included for each sample
as a measure of the success of bisulfite conversion of that
sample [22]. A cycle threshold for Alu of <23 was the
sample inclusion criteria [25,26]. PRDM5 is on the reverse





PRDM5 and beta catenin immunohistochemistry
Tissue sections were obtained from formalin-fixed paraffin
embedded (FFPE) blocks. Antigen retrieval was performed
at low pH (pH6, Reveal decloaker; Biocare Medical, CA,
USA) for 15mins at 105 °C. H2O2 and Sniper were used to
facilitate endogenous peroxidase and protein blocks
respectively. PRDM5 antibody (anti-PRDM5, LS-1982,
Lifespan BioSciences, Seattle, USA) was manually
applied at 1/750 dilution and left for 1 hour. MACH3
Rabbit secondary antibody probe and polymer was
applied for 10 and 20 minutes respectively (Biocare
Medical, CA, USA), and DAB chromagen (Biocare Medical,
CA, USA) was applied for 5 minutes. Beta-catenin antibody
(anti-Beta-catenin 224 M16 (14) Cell Marque, California,
USA) was manually applied and left for 1.5 hrs. MACH1
Rabbit secondary antibody probe and polymer was
applied for 15 and 30 minutes respectively, and DAB
was applied for 8 minutes. Sections were counterstained
with haematoxylin. Slides were examined by an expert
gastrointestinal pathologist and scored as either posi-
tive or negative depending on presence or absence of
PRDM5 staining, and presence of nuclear beta-catenin
was observed and scored either positive or negative
accordingly.Statistical analysis
Significant differences between categorical data were
analysed with Fisher‘s exact test or Pearson’s chi-squared
test where appropriate. Significance between continuous
data was analysed by a student’s t-test. P values <0.05 were
considered significant.
Results
Clinical and molecular findings of cancer cohorts
Clinical and molecular differences between the BRAF
mutant and BRAF wild type cohorts concurred with
previous findings [17,18]. The BRAF mutant cancers
had an older age of onset, a propensity to affect females, a
frequent proximal tumour location, an earlier stage at
presentation and a mucinous histology compared to BRAF
wild type cancers (Table 1). As expected, BRAF mutant
cancers were predominantly CIMP high and had a lower
rate of p53 mutation compared to BRAF wild type cancers
(Table 1).
The BRAF mutant cohort was comprised of 120 MSI
(56.1%) and 94 MSS (43.9%) cancers (Table 1). When
clinical and molecular parameters were considered
within this cohort with microsatellite status considered,
the differences again correlated with previous findings
[17,18]. BRAF mutant/MSS cancers affected patients at a
younger average age, more frequently presented at advanced
stages and were less commonly proximally located than
BRAF mutant/MSI cancers (Additional file 1: Table S1).
Additionally, BRAF mutant/MSS cancers were not as fre-
quently CIMP high, but were more frequently p53 mutant
compared to BRAF mutant/MSI cancers (Additional file 1:
Table S1).
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PRDM5 was methylated in 77/214 (36.0%) BRAF mutant
cancers compared to 4/122 (3.3%) BRAF wild type
cancers (p < 0.0001). Similarly, the average percentage
of methylated reference (PMR) scores which indicates
the extent of methylation of a cancer relative to a
methylase treated reference sample, was significantly
higher in the BRAF mutant compared to the BRAF
wild type cohort (27 vs 3; p < 0.0001) (Table 1). There
was no significant difference in PRDM5 methylation rates
within the BRAF mutant cohort when stratified for
microsatellite status (Additional file 1: Table S1).
BRAF mutant cancers that had methylated PRDM5
were more likely to present at advanced stages compared
to BRAF mutant cancers with unmethylated PRDM5
(AJCC stage III/IV: 29/65, 44.6% vs 31/105, 29.5%; p < 0.05)
(Table 2). PRDM5 methylation correlated with CIMP high.
CIMP high was strongly prevalent in the BRAF mutant/
MSI cancers (at 86%), therefore this was evident in the
BRAF mutant/MSS cohort (61% CIMP high rate) where
CIMP high was more frequent in PRDM5 methylated com-
pared to unmethylated cancers (27/36, 75.0% vs 27/53
50.9%; p = 0.03) (Additional file 1: Table S2).
PRDM5 protein expression in cancer cohorts
Immunohistochemical analysis of PRDM5 protein
expression in adjacent normal mucosa showed it was
routinely present within the crypt bases. Interestingly,
there was substantial loss of protein expression in both
the BRAF mutant (92/97, 94.5%) and BRAF wild type
(39/44, 88.6%) cancer cohorts (Figure 1).
Of the 10 cancers with retained PRDM5 protein
expression, 9 had unmethylated PRDM5. The high rateTable 2 Comparison of clinical and molecular features of
BRAF mutant cancers stratified by PRDM5 methylation






N BRAF mutant cancers 77/214 (36.0%) 137/214 (64.0%)
Average Age 72.7 75.0 0.1
Gender (Female) 48/77 (62.3%) 91/137 (66.4%) 0.6
Location (Proximal) 62/72 (86.1%) 102/120 (84.2%) 1.0
AJCC stage I/II 36/65 (55.4%) 74/105 (70.5%) <0.05
AJCC stage III/IV 29/65 (44.6%) 31/105 (29.5%)
Mucinous 9/34 (26.5%) 28/62 (45.2%) 0.08
Differentiation (poor) 15/34 (44.1%) 23/62 (37.1%) 0.5
MSI High 37/77 (48.1%) 83/137 (60.6%) 0.09
CIMP High 59/73 (80.8%) 95/132 (72.0%) 0.2
p53 Mutation 13/39 (33.3%) 15/68 (22.1%) 0.3
Nuclear Beta-Catenin 16/33 (48.5%) 20/59 (33.9%) 0.2
Significant p values indicated in bold text.of PRDM5 protein loss compared to the rate of methylation
across all cancers, and the high frequency of absent
PRDM5 protein expression observed in unmethylated
cancers, clearly indicates that other mechanisms besides
methylation are contributing to PRDM5 protein down-
regulation.
PRDM5 methylation and protein expression in polyp
cohorts
Fifty-nine serrated type precursor lesions (19 MVHPs,
20 SSAs, 20 TSAs), and forty conventional type precursor
lesions (20 TAs, 20 TVAs) were included in the analysis.
Molecularly, the serrated polyps were significantly more
methylated and BRAF mutant as expected, and all polyp
subtypes had a low KRAS mutation rate (Table 3).
Clinically, the TVAs and TSAs were more likely to be
larger and distally located (Additional file 1: Table S3).
Methylation and protein expression of PRDM5 was
analysed across all polyp subgroups to determine
whether down-regulated PRDM5 was an early event in
tumourigenesis and in which polyp type or pathway this
was mostly occurring in.
PRDM5 was methylated in 2 of each of the three serrated
polyp subtypes to give an overall methylation rate of 10%
(6/59) in the serrated polyps compared to the lack of
methylation in both subtypes of conventional polyps (0/40)
(p = 0.08). The average PMR of methylated PRDM5 was
significantly higher in all serrated polyp subtypes compared
to the conventional polyps (p = 0.01) (Table 3).
PRDM5 protein expression was reduced across the
serrated SSAs and TSAs, and conventional TAs and
TVAs polyp subgroups at similar frequencies (an average
of 59%). MVHPs which are the earliest form of serrated
lesion, had a lower rate of loss (at 26%) compared to
SSAs (60%) and TSAs (45%), which suggests there is a
progressive down-regulation of PRDM5 with advancing
disease (Table 3). Due to the greater rates of PRDM5
protein loss compared to methylation, other mechanisms
are contributing to this silencing especially in the
conventional polyps, as was seen in the cancer cohorts.
As expected, the rate of BRAF V600E mutation and
CIMP high was significantly more common in serrated
type polyps than conventional polyps (both p < 0.0001),
and KRAS mutation in codons 2 and 3 was relatively
low across both serrated and conventional polyp types
(8% and 10% respectively) (Table 3).
PRDM5 mutation analysis
A publicly available database was searched for presence
of PRDM5 mutations in colorectal cancer. cBioPortal
(www.cBioPortal.org) [27] incorporates data from The
Cancer Genome Atlas Network’s colorectal cancer study
[28] and Seshagiri et al. 2010 [29]. Collectively there are
296 colorectal cancers with somatic mutation data that
Figure 1 PRDM5 immunohistochemistry. A demonstrates the
normal pattern of staining in non-neoplastic colonic mucosa. Down
arrows indicate strong nuclear and cytoplasmic staining for PRDM5
in scattered cells predominantly in the crypt bases. Up arrowheads
indicate incidental melanosis coli in the lamina propria. B is a
representative area of a colorectal carcinoma negative for PRDM5.
C is a representative area of a colorectal carcinoma positive for
PRDM5, showing scattered cells with strong cytoplasmic and/or
nuclear staining. (Original magnification: x200).
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PRDM5 mutations were reported from 6 cancer samples
(2.0% mutation rate) that were all BRAF wild type. These
mutations were spread along the length of the gene and
no two were similar. Due to the low rate of PRDM5
mutation found, this type of analysis was not extended to
this study’s cancer or polyp cohorts.
Presence of nuclear beta-catenin in cancer and polyp
subgroups
Nuclear beta-catenin as a surrogate of Wnt pathway
activation was present in 39% (36/92) BRAF mutant
cancers which was significantly lower than the rate
observed in BRAF wild type cancers at 86% (36/42)(p < 0.0001) (Table 1). As expected, there was also a
significantly reduced rate of nuclear beta-catenin in
serrated compared to conventional polyps (3/59, 5%
vs 26/40, 65%) (p < 0.0001) (Table 3).
Due to previous correlations of methylated PRDM5
with presence of active beta-catenin and exogenous
PRDM5 causing a decrease in downstream Wnt reporter
assays [8], presence of methylated PRDM5 and nuclear
beta-catenin was assessed within the cancer cohorts.
There was no significant association of nuclear
beta-catenin occurring in PRDM5 methylated compared
to unmethylated BRAF mutant cancers (16/33; 49% vs
20/59, 34%) (p = 0.2) (Table 2). Only when stratified
for MSI status, was a correlation observed with a
higher rate of nuclear beta-catenin in PRDM5 methylated
compared to unmethylated BRAF mutant/MSI cancers
(13/21, 62% vs 12/38, 32%) (p = 0.03) (Additional file 1:
Table S2). No correlation with presence of nuclear
beta-catenin and methylated PRDM5 was seen in BRAF
mutant/MSS cancers.
Discussion
This study investigated a large series of molecularly sub-
typed colorectal cancers and precursor lesions for the
presence of PRDM5 methylation and protein expression.
We found the PRDM5 promoter region was substantially
methylated in BRAF mutant cancers of the serrated path-
way whereas minimal levels of methylation were detected
in the BRAF wild type cancers of the traditional pathway.
This is the first study to show that a particular subgroup
of colorectal cancer has a comparably high rate of PRDM5
methylation as previously found in other cancers such as
lung, breast, liver and gastric cancer [2,4,8,9].
PRDM5 methylation was evident in a small proportion
of serrated type polyps which indicates this may be an
early event in tumourigenesis in the serrated pathway.
The frequency of BRAF mutation and CIMP increased
from serrated polyp to cancer as expected. The frequency
of PRDM5 methylation also increased from serrated
precursor lesion to BRAF mutant cancers at a similar
proportion which suggests that PRDM5 methylation
associates with advancing disease in cancers of the
serrated pathway. Furthermore, there was an association
of PRDM5 methylation being more prevalent in BRAF
mutant cancers presenting at late compared to early stages
which further indicates epigenetic regulation of PRDM5
may influence disease progression in the serrated pathway.
This association was also seen in a previous study where
PRDM5 methylation was more common in high grade
breast and liver cancers [2].
The absence of PRDM5 methylation found in conven-
tional adenomas and the low rate seen in BRAF wild
type cancers indicates that PRDM5 methylation is not
an important event in traditional pathway cancers. This
Table 3 PRDM5 methylation and expression and other molecular features of serrated and conventional polyp subgroups
Serrated Polyps Conventional Adenomas P value
MVHP SSA TSA TVA TA Serrated vs conventional
N 19 20 20 20 20 -
PRDM5 Methylation 2 (11%) 2 (10%) 2 (10%) 0 0 0.08
PRDM5 Average 3.4 2.2 3.6 1.1 0.4 0.01
PMR score
PRDM5 IHC 5 (26%) 12 (60%) 12 (60%) 12 (60%) 11 (55%) 0.5
Negative Expression
BRAF mutation 18 (95%) 17 (85%) 13 (65%) 0 0 <0.0001
KRAS mutation 0 1 (5%) 4 (20%) 3 (15%) 1 (5%) 1.0
CIMP High 2 (11%) 12 (60%) 9 (45%) 0 0 <0.0001
Nuclear Beta-Catenin 0 0 3 (15%) 17 (85%) 9 (45%) <0.0001
Significant p values indicated in bold text.
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cancers, at 3%, was similar to the low frequency found
in the one other study that investigated primary colorectal
cancers [4], and others have concluded that there is only a
negligible rate of PRDM5 methylation in colorectal cancer
based on cell line analysis [8]. The findings from this study
highlights the importance of stratifying for molecular
subtype with analysis of molecular markers involved in
colorectal cancer as it is a heterogenous disease comprised
of several clinically and genetically distinct subtypes.
Although the KRAS mutation rate was minimal in the
conventional adenoma cohorts, similarly low rates,
particularly for TAs, have been previously found [20,30],
and wide variations of KRAS mutation rates in adenomas
have been reported [31-33].
CIMP is highly prevalent in cancers of the serrated
pathway, particularly those that are microsatellite unstable.
When the BRAF mutant cancers were stratified for MSI
status, it was apparent that PRDM5 methylation correlated
with CIMP. However, it is unlikely that PRDM5 methyla-
tion is merely a passenger event of CIMP. This is due to
there being a considerable presence of PRDM5methylation
and transcript down-regulation in several non-CIMP
cancer types [2,4,8,9], and there is a lack of reported
PRDM5 methylation in other CIMP related cancers
such as glioma. Additionally, the substantial loss of
PRDM5 protein expression found in this study, suggests
that potentially methylation and loss of PRDM5 is highly
relevant in tumourigenesis [34].
Endogenous PRDM5 protein expression was routinely
detected in normal tissue sections in this study which
concurs with a previous investigation that found PRDM5
transcript expression was prevalent in several normal
tissues [8]. Interestingly the vast majority of cancers
in both the BRAF mutant and BRAF wild type cancer
cohorts lacked PRDM5 protein expression. Absent expres-
sion was also widespread in both serrated and conventionalpolyps, although this rate of downregulation was less than
that in the cancers. MVHPs which are the earliest form of
serrated lesion and may give rise to SSAs, had the
least frequency of absent PRDM5 protein expression,
and overall this analysis demonstrates an early and linear
progression of downregulated PRDM5 with advancing
disease across all colorectal subgroups of both the serrated
and traditional pathways.
This frequent loss of PRDM5 protein expression seen
by immunohistochemistry is concordant with findings
of a previous study that investigated expression in 18
colorectal cancers that were not molecularly subtyped
[10]. However, half of this study’s normal sections had
no observed endogenous protein which may indicate
the inability of the antibody used to reliably detect
protein within their cancer samples. Of the 10 cancers in
the present study that retained PRDM5 protein expression,
there was 90% concordance with these cancers being
unmethylated. The one cancer that was methylated but still
expressed PRDM5 protein may be in the seeding stages of
methylation, and although the relatively few CpG sites
covered by the methylight assay were methylated, they
were not sufficient to fully silence protein expression.
Additionally, the cancers that were methylated with
concordant absent expression, may represent the presence
of a more global methylation pattern driving protein loss
in these cancers. Similar incidences of methylated gastric
and esophageal cancer cell lines showing positive
transcript expression has been observed [8]. This study’s
methylight assay was in very close proximity to the MSP
of Shu et al’s [8] in the promoter region which helps
to further suggest that in some cancers, extensive
methylation over the promoter is required for complete
down-regulation.
Previous studies have mostly analysed PRDM5 transcript
expression as a measure of the extent of silencing [2,4,8,35].
Although one reported similar findings to this current
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in unmethylated gastric cancers [4], concordance was found
between reduced transcript expression and methylation of
nasopharyngeal cancers, and therefore silencing induced
primarily by methylation was concluded [8]. This current
study analysed protein expression which is a more relevant
determinant of the functional endpoint state of the gene
and it reflects any post translational modifications that may
have taken place. Results showed a far greater rate of loss
compared to methylation frequency, indicating that in
colorectal cancer methylation is just one of the mechanisms
responsible for this.
PRDM5 mutation events contribute to brittle cornea
syndrome and neutropenia [3,7], however they have not
been analysed in cancer types previously. This study utilised
a publicly available database, cBioPortal [27], which incor-
porates data from two large series of colorectal cancers
[28,29]. Overall a low rate of mutation was found and there
was no identifiable mutational hotspot which indicated this
mechanism is not a common cause of down-regulation.
However, all mutations were present in BRAF wild type
cancers which may still indicate this mechanism is of some
relevance in traditional pathway cancers.
PRDM5 is located on chromosome 4q27 which is
within a region commonly deleted in colorectal cancer
[36,37]. Analysis of recent SNP array data, revealed loss
over this locus in 33% BRAF mutant/MSS and 44%
BRAF wild type cancers [38], which suggests gene deletion
may also contribute to the levels of down-regulation
observed. It was found that the colorectal cancer cell line,
SW480, lacked PRDM5 expression due to methylation of
histone H3K27 and not as a result of a methylated
promoter region [4]. Therefore, histone modification
events that can alter chromatin structure and result in
gene suppression provide a further mechanism of PRDM5
silencing. Additionally, small and long regulatory RNAs
may be acting at both the post-transcriptional and
pos-translational stages to effect gene and /or protein
expression [39], as well as one of the many other
post-translational modifications such as acetylation
and that could be taking place to affect expression.
The Wnt pathway is one of the most aberrantly upregu-
lated pathways present in colorectal cancer [28]. Previous
findings have shown that PRDM5 can interact with a
variety of genes involved in inhibition of the Wnt
pathway [6], PRDM5 loss results in an increased number
of intestinal adenomas on an upregulated Wnt back-
ground [10], and methylated PRDM5 has been correlated
with presence of active beta-catenin in cancer cell lines
[8]. In this study, methylated PRDM5 associated with
presence of nuclear beta-catenin in the BRAF mutant/
MSI cancers (Additional file 1: Table S2). These cancers,
through their heavily methylated phenotype have
been found to methylate other inhibitors of the Wntpathway such as DKK1 and AXIN2 [40,41], which indi-
cates epigenetic regulation of the Wnt pathway may be
more prevalent in the BRAF mutant/MSI compared to
other CRC subtypes.Conclusions
This is the first study that has analysed the rate of
PRDM5 methylation and protein expression in a large
and well characterized series of colorectal cancer and
polyp subgroups.
PRDM5 methylation was found to be an early event
with progressive acquisition in BRAF mutant cancers of
the serrated pathway. Furthermore, PRDM5 protein
levels were substantially reduced across both serrated
and conventional polyp types and more so in BRAF
mutant and wild type cancers. This indicates that
down-regulation is initiated early in tumourigenesis
and is progressive with disease advancement in both
the serrated and traditional pathways. Epigenetic
modification may be contributing to gene silencing in
a proportion of BRAF mutant cancers and the large extent
of absent protein expression indicates other mechanisms
are also responsible for PRDM5 down-regulation. PRDM5
mutation was present in a small percentage of BRAF wild
type cancers and this may be a cause of downregulation
in this cancer subgroup. Overall, this investigation
highlights PRDM5 as an important tumour suppressor
gene in colorectal cancer.Additional file
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